Penserra Capital Management LLC Apellis Pharmaceuticals, Inc. Transaction History

Penserra Capital Management LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 15, 2022	SELL	$30.74 - $49.16 $61,172 - $97,828	-1,990 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$31.4 - $69.84 $5,024 - $11,174	160 Added 8.74%	1,990 $65,000
Q2 2021 Aug 12, 2021	BUY	$40.9 - $64.9 $613 - $973	15 Added 0.83%	1,830 $115,000
Q1 2021 May 13, 2021	BUY	$40.8 - $57.39 $2,652 - $3,730	65 Added 3.71%	1,815 $77,000
Q4 2020 Feb 12, 2021	BUY	$30.79 - $57.2 $33,992 - $63,148	1,104 Added 170.9%	1,750 $100,000
Q3 2020 Nov 13, 2020	BUY	$25.89 - $33.65 $16,724 - $21,737	646 New	646 $19,000

308

115M

3.85M

1.09M

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.64B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Penserra Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Penserra Capital Management LLC with notifications on news.